Entry into a Material Definitive Agreement

Business Context and Reporting Period

This Form 8-K reports on events occurring on April 20, 2026, regarding First Tracks Biotherapeutics, Inc. (the "Company"). On this date, AnaptysBio, Inc. completed a pro rata spin-off of the Company to its shareholders. Simultaneously, the Company completed a private placement of common stock. The Company is a biotechnology firm focused on developing therapeutics for autoimmune and inflammatory diseases, including clinical-stage programs for rosnilimab, ANB033, and ANB101.

Key Financial Metrics and Capital Structure

  • Private Placement Proceeds: The Company issued 5,791,478 shares and the Selling Stockholder (EcoR1 Capital Fund Qualified, L.P.) sold 4,705,575 shares at a purchase price of $13.81 per share.
  • Cash Allocation: Under the Separation and Distribution Agreement, First Tracks Biotherapeutics received $100.0 million in cash and cash equivalents from AnaptysBio.
  • Equity Issuance: 29,100,802 shares of Common Stock were issued to AnaptysBio in consideration for the transfer of the biopharma business entities.
  • Future Milestone Rights: The Company retained rights to receive up to $35.0 million in milestone payments under the Vanda Collaboration for future regulatory approvals and sales.
  • Revenue and Profit: The filing text does not provide specific revenue, profit, or operating margin figures for the Company as a standalone entity for a reporting period.

Material Changes and Corporate Actions

  • Spin-Off Completion: The Company separated from AnaptysBio. AnaptysBio retained the "Royalty Management Co. Business" (including Jemperli and imsidolimab royalties), while First Tracks Biotherapeutics retained the biotechnology development business.
  • Asset and Liability Transfer: First Tracks Biotherapeutics assumed liabilities related to its business operations post-spin-off, while AnaptysBio retained liabilities related to its pre-spin-off operations and the Royalty Management business.
  • Executive Appointment: Ajim Tamboli was appointed Chief Financial Officer effective April 20, 2026.
  • Corporate Governance: The Company adopted an Amended and Restated Certificate of Incorporation and Bylaws effective upon the spin-off.

Management Commentary and Agreements

  • Transition Services: A Transition Services Agreement was executed, under which First Tracks Biotherapeutics will provide services (digital technology, HR, finance, etc.) to AnaptysBio for up to two years to ensure an orderly transition.
  • Indemnification: Mutual indemnification provisions were established between the Company and AnaptysBio regarding liabilities allocated to each party and breaches of the separation agreements.
  • Registration Rights: A Registration Rights Agreement was entered into with private placement investors, requiring the Company to file a registration statement for the resale of shares within 45 days of the distribution date.
  • Executive Compensation: The new CFO, Mr. Tamboli, received an initial annual base salary of $516,000, a target cash bonus of up to 40%, and equity awards valued at $2,550,000.

Investor Verification Checklist

  • Verify the final cash balance of $100.0 million received from AnaptysBio and the total proceeds from the private placement.
  • Review the specific terms of the Transition Services Agreement to understand ongoing operational dependencies on AnaptysBio.
  • Confirm the status of the $35.0 million potential milestone payments from the Vanda Collaboration and the conditions required to trigger them.
  • Examine the Separation and Distribution Agreement for any contingent liabilities or delayed asset transfers that could impact future financial statements.
  • Monitor the filing of the registration statement for the private placement shares as required within 45 days of April 20, 2026.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.